Bright Minds Biosciences (DRUG) Research & Development (2020 - 2026)

Bright Minds Biosciences has reported Research & Development for 7 years, with the latest figure at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 432.65% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.0 million (up 683.14% YoY), and the FY2025 full-year result was $8.1 million, up 831.13% from the prior year.
• Research & Development for Q1 2026 stood at $9.5 million, up from $4.1 million in the prior quarter.
• The five-year high for Research & Development was $9.5 million in Q1 2026, with the low at -$414373.2 in Q2 2024.
• Historically, Research & Development has averaged $1.9 million across 5 years, with a median of $1.1 million in 2022.
• Annual changes were most pronounced in 2024 — Research & Development tumbled 152.98% — and 2025, when it surged 2188.44%.
• Bright Minds Biosciences' Research & Development stood at $1.1 million in 2022, then declined by 16.29% to $900190.9 in 2023, then dropped by 16.87% to $748325.8 in 2024, then soared by 442.43% to $4.1 million in 2025, then jumped by 134.39% to $9.5 million in 2026.
• The last three Research & Development figures came in at $9.5 million (Q1 2026), $4.1 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.